PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to…
Leveraging AI to Better Identify Fraud, Waste, and Abuse (FWA) Key Points Responsible AI implementation brings clarity to pharmacy benefit strategy when it is…
How Payers Can Adapt to the Rapidly Changing GLP-1 Landscape Key Points GLP-1 medications are driving rapid utilization growth that traditional pharmacy benefit designs are…
Rethinking What “Data-Driven Strategy” Means in Pharmacy Benefits Key Points Many leaders use data to validate strategy, but the greatest value emerges when analytics…
An Overview of Regulatory and Legislative Updates For Plan Sponsors Key Points The ESI settlement creates new options for plan sponsors, but few protections…
Will Additional SMA Gene Therapies Affect Payers’ Budgets? Key Points: SMA treatment has shifted from supportive care to high-cost disease-modifying and gene therapies, with…
Quickly Identify Inappropriate Concurrent Use with Artemetrx Data and Analytics Key Points: Inappropriate concurrent medication use can drive unnecessary cost and increase safety risks,…
